Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a clinical-stage biotechnology company advancing targeted therapies for cancer treatment, with a focus on immuno-oncology and precision medicine. This page provides investors and industry stakeholders with timely updates on the company’s clinical trials, strategic collaborations, and regulatory milestones.
Access curated press releases and news articles covering Curis’s pipeline developments, including its lead candidate emavusertib, partnership updates with Aurigene and Genentech, and financial performance. The resource is designed to help users track progress across hematologic and solid tumor indications while staying informed about licensing agreements and scientific advancements.
Content spans clinical trial results, FDA designations, earnings reports, and research publications. Bookmark this page for direct access to verified updates on Curis’s innovative approaches to modulating cancer pathways and expanding treatment options.
Curis (NASDAQ: CRIS) reported its Q2 2025 financial results and business updates, focusing on the development of emavusertib, their oral IRAK4 inhibitor. The company reported a net loss of $8.6 million ($0.68 per share), an improvement from $11.8 million loss in Q2 2024. Revenues increased to $2.7 million, up from $2.5 million year-over-year.
Key operational highlights include continued enrollment in the TakeAim Lymphoma study for PCNSL patients, completion of enrollment in the TakeAim Leukemia Phase 1/2 study, and plans to initiate a new clinical study combining emavusertib with BTKi in CLL patients. The company's cash position stands at $10.1 million, with recent offerings extending runway into Q1 2026.
Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), has scheduled its second quarter 2025 financial results announcement for August 5, 2025, at 8:00 a.m. ET.
The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Participants can join via phone or access the live audio webcast through the company's website. A replay will be available at www.curis.com.
Curis (NASDAQ: CRIS) has announced a combined $7.0 million financing through a registered direct offering and concurrent private placement. The company will issue 1,538,460 shares of common stock in a registered direct offering and unregistered pre-funded warrants for up to 1,538,461 shares in a private placement.
The transaction includes Common Warrants to purchase up to 3,076,921 shares at an exercise price of $2.15 per share. The combined purchase price is $2.275 for one share and associated Common Warrant, and $2.265 for one Pre-Funded Warrant and associated Common Warrant. The offerings are expected to close around July 3, 2025.
Proceeds will support research, development, working capital, and general corporate purposes for Curis's development of emavusertib, an oral IRAK4 inhibitor.
Curis (NASDAQ: CRIS) has announced the approval of inducement stock options for its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy. The grant, approved by the Board of Directors, allows Dr. Hamdy to purchase 200,000 shares of Curis common stock at an exercise price equal to the closing price on May 1, 2025.
The stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary and an additional 6.25% vesting every three months thereafter, contingent on Dr. Hamdy's continued employment. The grant was made outside of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan as an inducement for Dr. Hamdy's employment.
Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), has scheduled its first quarter 2025 financial results announcement for May 6, 2025, at 8:00 a.m. ET.
The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Investors can participate through:
- U.S. dial-in: (800)-836-8184
- International dial-in: (646)-357-8785
- Live audio webcast: Available on the Curis website's events & presentations section
Emavusertib, their key drug candidate, is an oral small molecule IRAK4 inhibitor. A replay of the conference call will be accessible at www.curis.com.
Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference on April 9, 2025.
The company's President and CEO, James Dentzer, will engage in two key sessions: a fireside chat titled 'All Bets on IRAK4' at 4:30 PM ET, followed by a corporate presentation at 5:00 PM ET. Both events will be accessible via live webcast and archived replay through the Events & Presentations section of Curis's website.
Curis (NASDAQ: CRIS) reported its Q4 2024 business update and financial results. The company successfully concluded discussions with FDA and EMA regarding potential accelerated approval path for emavusertib in PCNSL, which received Orphan Drug Designation in both regions.
Key clinical highlights include:
- In BTKi-experienced PCNSL patients: 9 of 13 showed tumor reduction, including 6 objective responses
- In BTKi-naïve PCNSL patients: 5 of 6 demonstrated tumor reduction
- In R/R AML study: 10 of 19 evaluable patients achieved objective response
Financial results for Q4 2024:
- Net loss of $9.6 million ($1.25 per share)
- Revenue of $3.3 million from Erivedge royalties
- Cash position of $20.0 million as of December 31, 2024
Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has scheduled its Q4 2024 financial results announcement for March 31, 2025, at 8:00 a.m. ET. The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Investors can access the call by dialing (800)-836-8184 from the US or (646)-357-8785 from other locations. A live webcast will be available on the Curis website's investor section, with a replay accessible at www.curis.com.
Curis (NASDAQ: CRIS) presented additional data from the TakeAim Leukemia study of emavusertib in relapsed/refractory Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting. The updated results include data from 21 patients with FLT3 mutation treated at the Recommended Phase 2 Dose of 300 mg BID.
Among 19 response-evaluable patients, 10 showed objective responses: 6 complete remissions (CR), 2 CR with incomplete/partial hematological recovery, and 2 morphologic leukemia-free state. Prior therapies of responders included Venetoclax, HMA, and FLT3i. Two patients proceeded to allogenic stem cell transplantation, with 7 of 10 responses observed at first assessment.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
